Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
07. Mai 2019 16:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...
Novan Announces Promising Clinical Results with SB414
20. August 2018 06:30 ET
|
Novan, Inc.
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
15. Mai 2018 08:10 ET
|
Novan, Inc.
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be...
Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
05. Dezember 2017 08:35 ET
|
Novan, Inc.
MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 1b clinical...
Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
18. Oktober 2017 07:05 ET
|
Novan, Inc.
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
27. April 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...